GSK (GSK) vs Royalty Pharma (RPRX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Royalty Pharma (RPRX) has outperformed GSK (GSK) over the past year, gaining 56.1% versus a gain of 7.4%. Over five years, RPRX leads with a +46.4% price change compared with +19.3% for GSK. GSK is the larger company by market cap ($93.49 billion vs $32.97 billion), about 2.8 times the size.
On valuation, GSK trades at a lower forward P/E (9.4x vs 9.9x for Royalty Pharma). Royalty Pharma offers the higher dividend yield (1.60% vs 1.46%).
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | GSK | RPRX |
|---|---|---|
| Share price | $46.67 | $57.05 |
| Market cap | $93.49B | $32.97B |
| 1-day change | +0.27% | +1.49% |
| YTD return | -5.10% | +45.47% |
| 1-year return | +7.36% | +56.05% |
| 5-year return | +19.30% | +46.42% |
| P/E ratio (TTM) | 14.72 | 30.35 |
| Forward P/E | 9.44 | 9.95 |
| EPS (TTM) | $3.17 | $1.88 |
| Dividend yield | 1.46% | 1.60% |
| Annual dividend | $0.68 | $0.91 |
| Revenue (latest FY) | — | $2.38B |
| Revenue growth (YoY) | — | +5.06% |
| Net income (latest FY) | — | $770.95M |
| Operating margin | — | 65.58% |
| Net margin | — | 32.42% |
| 52-week high | $61.70 | $64.38 |
| 52-week low | $42.85 | $35.23 |
| Distance from 52-week high | -24.37% | -11.39% |
| Analyst consensus | hold | strong_buy |
| Avg. price target upside | +27.14% | +14.60% |
| Average volume | 3.85M | 2.92M |
| Shares outstanding | 2.00B | 445.28M |
| Employees | 66,841 | 100 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- GSK is about 2.8 times larger than Royalty Pharma by market value ($93.49B vs $32.97B).
- RPRX has outperformed GSK by 48.7 percentage points over the past year.
- Royalty Pharma trades at a higher earnings multiple (30.3x vs 14.7x trailing P/E).
About GSK
GSK stock →GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, specialty medicines, and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through Commercial Operations and Total R&D segments.
Health Care · Biotechnology: Pharmaceutical Preparations · 66,841 employees
About Royalty Pharma
RPRX stock →Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovation in the biopharmaceutical industry in the United States. Its portfolio consists of royalties on approximately 35 marketed therapies and 20 development-stage product candidates that address various therapeutic areas, such as rare disease, oncology, neuroscience, infectious disease, hematology, and diabetes.
Health Care · Biotechnology: Pharmaceutical Preparations · 100 employees
GSK vs RPRX FAQ
Which is bigger, GSK or Royalty Pharma?
GSK (GSK) is larger, with a market capitalization of $93.49B compared with $32.97B for Royalty Pharma (RPRX).
Which stock has performed better over the past year, GSK or RPRX?
RPRX returned +56.05% over the past 12 months, compared with +7.36% for GSK (price return, excluding dividends). Past performance does not predict future results.
Which has the lower P/E ratio, GSK or RPRX?
GSK has the lower trailing P/E at 14.7, versus 30.3 for RPRX. A lower P/E is not by itself a sign of a better investment; it can reflect slower expected growth or higher risk.
Which pays a higher dividend, GSK or Royalty Pharma?
Royalty Pharma has the higher yield at 1.60%, compared with 1.46% for GSK.
Are GSK and Royalty Pharma in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.